Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 17/20 | 0.47 |
| ▸ | JAK1 | P23458 | 15/20 | 0.47 |
| ▸ | JAK2 | O60674 | 13/20 | 0.46 |
| ▸ | TYK2 | P29597 | 9/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27148737 | 1.00 | JAK3 (0.47) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL9989736 | 0.83 | JAK2 (0.55) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL14603782 | 0.83 | DYRK1A (0.38) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL17129858 | 0.82 | JAK1 (0.69) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL17122720 | 0.82 | JAK1 (0.69) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL31656244 | 0.81 | JAK3 (0.49) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL27137498 | 0.81 | JAK3 (0.49) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL31656245 | 0.81 | JAK3 (0.49) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL14603824 | 0.77 | CTSB (0.36) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL15655134 | 0.77 | IRAK4 (0.34) | JAK3JAK1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4582425-A1 | PRODRUG OF JAK KINASE INHIBITOR | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd (CN) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024041586-A1 | PRODRUG OF JAK KINASE INHIBITOR | 启元生物(杭州)有限公司 | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | JAK1, JAK2, JAK3 | JAK3 3/4885JAK1 1/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.